Author: Alex Strauss

  • | |

    Advocacy Groups Say Mesothelioma Bill Falls Short

    Mesothelioma patient advocacy groups in the UK are not happy about a proposed new law aimed at helping some patients receive compensation for their illness. The bill now before the British Parliament would give mesothelioma patients who could not trace the origins of their disease to a liable company the opportunity to still receive some compensation through a fund paid for by insurance companies. The bill, which represents at least two years of negotiation with representatives of the British insurance industry, makes it mandatory for insurers to pay into the fund. While the bill still puts a cap on the amount of compensation a mesothelioma patient can receive, the cap is much higher than the previous government-funded program could provide. But…

  • | |

    Mesothelioma Surgeons Report New Biopsy Technique

    A team of surgeons in Maryland have demonstrated how using a standard biopsy tool in a new way could improve the biopsy process for certain mesothelioma patients. An aggressive cancer of the pleural lining around the lungs, malignant pleural mesothelioma usually requires a tissue biopsy to make a definitive diagnosis. Often this is done using a rigid tool called a thoracoscope inserted into the chest wall while the patient is under general anesthesia. However, mesothelioma doctors at Walter Reed National Military Medical Center detail the case of a 79-year-old suspected mesothelioma patient whose biopsy was done in a minimally-invasive way, under conscious sedation, thanks to the novel use of a standard tool. Although the patient had several of the common signs…

  • |

    New Serum Marker Could Improve Mesothelioma Diagnosis

    Japanese researchers believe they have found a way to diagnose a rare form of mesothelioma earlier using a simple blood test. Diffuse malignant peritoneal mesothelioma (DMPM), which represents about a fourth of all mesothelioma cases, is an aggressive malignancy that spreads across the lining of the abdomen. In most cases, DMPM is lethal within a year. The standard treatment for diffuse malignant peritoneal mesothelioma is cytoreductive surgery to remove as much of the mesothelioma as possible, followed by intraperitoneal chemotherapy to destroy residual cancer cells. In some studies, this approach has resulted in 5-year survival rates of 30 to 60 percent. However, it is most successful when it is performed early, while the primary mesothelioma tumor is more easily removed. Like all forms of…

  • |

    Asbestos Bans Influenced by Mesothelioma ‘Visibility’

    Why have some countries banned asbestos while others have not? A team of Korean researchers studying the question says it is likely influenced by perception of mesothelioma risk as well as what neighboring countries are doing. Medical authorities around the world agree that the mineral asbestos is directly linked to development of mesothelioma, a virulent cancer of the linings around organs. Most often found in the pleura encasing the lungs, mesothelioma is usually the result of on-the-job exposure to asbestos dust. Asbestos was once widely used in a variety of construction materials, including wallboard, paint, floor and ceiling tiles and cement blocks. Even in countries where asbestos is now banned, the presence of the material in existing buildings can pose a mesothelioma…

  • For Mesothelioma Staging PET/CT Tops PET/MRI

    Standard PET/CT beats PET/MRI for diagnosing and staging pleural tumors such as mesothelioma. That is the conclusion reached by a team of radiology researchers in Zurich who evaluated  the two imaging modalities side-by-side for a variety of different cancers, including mesothelioma. Positron emission tomography is a nuclear imaging technique that produces 3D images of functional or metabolic processes in the body. Patients are given a radioactive tracer (usually FDG, a molecule similar to glucose) and the PET machine detects concentrations of the tracer in body tissues. Because FDG is an analog of glucose, it will concentrate where metabolic activity is highest, often in cancer cells. The combination of PET with computed tomography, an X-ray imaging study that produces tomographic images or…

  • | |

    NUMB Gene May Suppress Mesothelioma

    Researchers at Shandong University in China have pinpointed the connection between low levels of the protein NUMB and a poor mesothelioma prognosis. NUMB is known to act as an anticancer protein in part by binding to the tumor suppressor p53 and preventing its breakdown. Low levels of the NUMB protein have been linked to several types of cancer. In the latest study, published in Oncology Reports, researchers measured the expression of NUMB in 39 tissue samples of epithelioid mesothelioma. The results were compared using immunohistochemistry (protein testing) to 22 normal pleural tissues. NUMB was found to be significantly lower in the mesothelioma cells and the tissue samples with the lowest expression of NUMB were associated with the poorest prognosis. At the…

  • |

    Mesothelioma Symptoms May Benefit from Tuberculosis Drugs

    Pleural effusion is the one of most uncomfortable and life-limiting symptoms of pleural mesothelioma. The buildup of fluid in the pleural space around the lungs, which can happen in late stage mesothelioma as well as several other types of cancer, limits breathing and can be painful. Effusion is often one of the primary reasons that mesothelioma patients in the late stages of the disease have trouble taking a full breath and complain of chest pain and fatigue. While pleural fluid can be drained off through thoracentesis or chemically absorbed through pleurodesis, these treatments are painful, risky, and not always effective. Now, a team of researchers in China say they may have discovered a non-invasive method for dealing with pleural effusion caused…

  • | |

    European Buildings May Be Safer by 2028

    A British politician says the country should stand behind a new European Parliament report calling for the removal of asbestos from all public buildings by 2028. Asbestos is the number one cause of mesothelioma and Britain has the highest mesothelioma rate in the world, with a death occurring about every five hours. An estimated 4,000 British people die of mesothelioma each year, a full 1,000 more than are typically seen in the U.S.  At greatest risk are the many people who have worked with or around asbestos in construction and various industrial jobs. But Britain’s high number of quickly-built, inexpensive, post-WWII era buildings – many of which are now crumbling – has also been blamed for the high mesothelioma rate. In…

  • |

    Study Lists Factors That Impact Mesothelioma Prognosis

    Predicting survival in mesothelioma patients does not have to be complicated. A new Parisian study suggests that simple-to-measure factors such as patient age and the histological subtype of the mesothelioma can be highly accurate prognostic indicators. The study followed 170 patients diagnosed with malignant pleural mesothelioma between 2000 and 2010 at Saint Antoine Hospital in Paris. Patients in the study were all treated non-surgically. For each patient, a list of parameters was recorded including age, gender, tobacco use, asbestos exposure, type and duration of symptoms, BMI, C-reactive protein levels and white blood cell and platelet counts.  Inflammation of the pleura (pachypleuritis) was also noted, along with the type of diagnostic surgical procedure, histological subtype, the way in which pleurodesis was performed (for…

  • |

    Predicting Mesothelioma Outcomes with Blood Tests

    Two separate teams of Japanese researchers are delving into the possibilities of blood serum indicators that could help predict outcomes in patients with malignant pleural mesothelioma. Mesothelioma is a rare but aggressive cancer caused by exposure to asbestos. Pleural mesothelioma, a cancer that starts on the lining around the lungs, is the most common form of the disease. It occurs most often in people who have inadvertently inhaled asbestos dust. Mesothelioma is highly resistant to conventional treatments. It is also difficult to predict which patients are likely to do well with standard therapies and which are not, which is referred to as prognosis. But researchers worldwide are continually searching for new ways to diagnose and predict the prognosis of patients with…